Skip to main content

Table 3 Impact of biomarkers on radiographic and erosive progression (ΔSvH ≥5 and ΔErosion ≥5)

From: Serum levels of 14-3-3η protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis

   ΔSvH ≥ 5 ΔErosion ≥ 5
Baseline variables Total, number at 60 m, number (%) RR (95 % CI) from GEE over time at 60 m, number (%) RR (95 % CI) from GEE over time
14-3-3η, ng/ml      
 <0.19 169 73 (43.2) 1 48 (28.4) 1
 0.19–0.50 31 12 (38.7) 0.86 (0.52–1.43) 10 (32.3) 0.93 (0.51–1.70)
 ≥0.50 115 74 (64.3) 1.57 (1.24–1.97) *** 60 (52.2) 2.01 (1.49–2.72) ***
14-3-3η, ng/ml      
 <0.19 169 73 (43.2) 1 48 (28.4) 1
 ≥0.19 146 86 (58.9) 1.40 (1.11–1.77) ** 70 (47.9) 1.77 (1.31–2.38) ***
14-3-3η, ng/ml      
 <0.50 200 85 (42.5) 1 58 (29.0) 1
 ≥0.50 115 74 (64.3) 1.60 (1.28–2.00) *** 60 (52.2) 2.04 (1.53–2.70) ***
Age, years      
 <65 198 81 (40.9) 1 62 (31.3) 1
 ≥65 117 78 (66.7) 1.71 (1.36–2.13) *** 56 (47.9) 1.51 (1.13–2.01) **
C-reactive protein, mg/L      
 ≤8.0 117 51 (43.6) 1 30 (25.6) 1
 >8.0 198 108 (54.5) 1.46 (1.12–1.90) ** 88 (44.4) 1.87 (1.31–2.66) ***
Anti-CCP2 status      
 Negative 190 85 (44.7) 1 59 (31.1) 1
 Positive 125 74 (59.2) 1.44 (1.14–1.80) ** 59 (47.2) 1.74 (1.31–2.33) ***
RF ≥40 IU/ml      
 Negative 176 76 (43.2) 1 51 (29.0) 1
 Positive 139 83 (59.7) 1.51 (1.20–1.90) *** 67 (48.2) 2.02 (1.50–2.72) ***
Anti-Sa status      
 Negative 246 110 (44.7) 1 76 (30.9) 1
 Positive 69 49 (71.0) 1.72 (1.38–2.14) *** 42 (60.9) 2.22 (1.69–2.92) ***
RF or anti-CCP2 positive      
 Negative 157 67 (42.7) 1 44 (28.0) 1
 Positive 158 92 (58.2) 1.53 (1.21–1.94) *** 74 (46.8) 2.02 (1.47–2.76) ***
14-3-3η ≥0.50 ng/ml and age ≥65 years      
 Both negative 117 34 (29.1) 1 24 (20.5) 1
 One positive 164 98 (59.8) 2.35 (1.71–3.23) *** 72 (43.9) 2.40 (1.61–3.57) ***
 Both positive 34 27 (79.4) 2.96 (2.07–4.24) *** 22 (64.7) 3.46 (2.21–5.42) ***
14-3-3η ≥0.50 and C-reactive protein >8.0 mg/L      
 Both negative 73 28 (38.4) 1 16 (21.9) 1
 One positive 171 80 (46.8) 1.25 (0.88–1.76) 56 (32.7) 1.58 (0.97–2.58)
 Both positive 71 51 (71.8) 2.21 (1.58–3.09) *** 46 (64.8) 3.48 (2.17–5.56) ***
14-3-3η ≥0.50 ng/ml and anti-CCP2      
 Both negative 163 68 (41.7) 1 45 (27.6) 1
 One positive 64 34 (53.1) 1.4 (1.04–1.89) * 27 (42.2) 1.74 (1.19–2.54) **
 Both positive 88 57 (64.8) 1.7 (1.32–2.20) *** 46 (52.3) 2.27 (1.62–3.16) ***
14-3-3η ≥0.50 ng/ml and RF      
 Both negative 165 69 (41.8) 1 44 (26.7) 1
 One positive 46 23 (50.0) 1.31 (0.93–1.86) 21 (45.7) 1.80 (1.19–2.72) **
 Both positive 104 67 (64.4) 1.68 (1.32–2.15) *** 53 (51.0) 2.32 (1.67–3.22) ***
14-3-3η ≥ 0.50 ng/ml and anti-Sa      
Both negative 185 75 (40.5) 1 51 (27.6) 1
One positive 76 45 (59.2) 1.36 (1.03–1.79) * 32 (42.1) 1.64 (1.15–2.34) **
Both positive 54 39 (72.2) 2.02 (1.57–2.59) *** 35 (64.8) 2.80 (2.04–3.85) ***
14-3-3η ≥ 0.50, “RF and/or anti-CCP2”      
 Both negative 152 64 (42.1) 1 41 (27) 1
 One positive 110 71 (64.5) 1.23 (0.87–1.74) 57 (51.8) 1.59 (1.04–2.44) *
 Both positive 53 24 (45.3) 1.71 (1.33–2.19) *** 20 (37.7) 2.34 (1.67–3.27) ***
14-3-3η ≥ 0.50, Age ≥65, C-reactive protein >8.0      
 All negative 43 11 (25.6) 1 7 (16.3) 1
 Only C-reactive protein positive 74 23 (31.1) 1.25 (0.67–2.32) 17 (23.0) 1.54 (0.71–3.36)
 Only 14-3-3η positive 34 16 (47.1) 1.87 (0.97–3.60) 10 (29.4) 2.18 (0.94–5.06)
 Only age positive 30 17 (56.7) 2.41 (1.31–4.43) ** 9 (30.0) 2.06 (0.86–4.89)
 Only C-reactive protein and age positive 53 34 (64.2) 2.97 (1.71–5.18) *** 25 (47.2) 3.27 (1.59–6.71) **
 Only 14-3-3η and C-reactive protein- positive 47 31 (66.0) 3.21 (1.85–5.59) *** 28 (59.6) 4.65 (2.33–9.29) ***
 Only 14-3-3η and age-positive 10 7 (70.0) 2.22 (1.02–4.84) * 4 (40.0) 2.47 (0.85–7.17)
 All positive 24 20 (83.3) 3.90 (2.25–6.78) *** 18 (75.0) 5.49 (2.73–11.08) ***
  1. *p <0.05, **p <0.01, ***p <0.001. ΔSvH progression in the total Sharp score modified by van der Heijde, ΔErosion progression in the erosion component of the Sharp score modified by van der Heijde, GEE general estimating equation, RF rheumatoid factor, Anti-CCP2 antibodies to citrullinated peptides, second generation